656257-46-4 Usage
General Description
The chemical 1-(2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenoxy]-ethyl)-pyrrolidine is a complex organic compound with a molecular structure that includes a pyrrolidine ring and a dioxaborolane ring. It also contains a phenoxy group and a tetramethyl substitution. This chemical likely has applications in the field of organic synthesis, particularly in the development of new pharmaceuticals, agrochemicals, and materials. It may also be used as a reagent in research laboratories for the synthesis of other organic compounds. Through its unique structure and properties, this chemical has the potential to contribute to advancements in various scientific and industrial fields.
Check Digit Verification of cas no
The CAS Registry Mumber 656257-46-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,5,6,2,5 and 7 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 656257-46:
(8*6)+(7*5)+(6*6)+(5*2)+(4*5)+(3*7)+(2*4)+(1*6)=184
184 % 10 = 4
So 656257-46-4 is a valid CAS Registry Number.
656257-46-4Relevant articles and documents
BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS
-
Page/Page column 148; 155-156, (2020/03/05)
This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt, N-oxide, isotopic derivative or prodrug thereof or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder. The invention also includes a combination thereof with another active agent such as a CDK inhibitor, including a CDK4/6 inhibitor, to treat a disorder mediated by the estrogen receptor, as described in more detail herein.
PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS
-
Page/Page column 91; 92; 93, (2015/06/25)
New pyrazolopyridmiin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
